Tissue Sealants - Medical Devices Pipeline Assessment, 2019

Table of Contents

• 1.1 List of Tables 5
• 1.2 List of Figures 8

2 Introduction 9

• 2.1 Tissue Sealants Overview 9

3 Products under Development 10

• 3.1 Tissue Sealants - Pipeline Products by Stage of Development 10
• 3.2 Tissue Sealants - Pipeline Products by Segment 11
• 3.3 Tissue Sealants - Pipeline Products by Territory 12
• 3.4 Tissue Sealants - Pipeline Products by Regulatory Path 13
• 3.5 Tissue Sealants - Pipeline Products by Estimated Approval Date 14
• 3.6 Tissue Sealants - Ongoing Clinical Trials 15

4 Tissue Sealants - Pipeline Products under Development by Companies 16

• 4.1 Tissue Sealants Companies - Pipeline Products by Stage of Development 16
• 4.2 Tissue Sealants - Pipeline Products by Stage of Development 18

5 Tissue Sealants Companies and Product Overview 20

• 5.1 Adhesys Medical GmbH Company Overview 20
• 5.2 Advanced Medical Solutions Group plc Company Overview 22
• 5.3 Aleo BME Inc Company Overview 23
• 5.4 Angiotech Pharmaceuticals Inc Company Overview 24
• 5.5 Arch Therapeutics Inc Company Overview 25
• 5.6 Arizona State University Company Overview 26
• 5.7 Baxter International Inc Company Overview 27
• 5.8 Biomedica Management Corp Company Overview 28
• 5.9 Boston University Company Overview 29
• 5.10 C. R. Bard Inc Company Overview 30
• 5.11 Calmare Therapeutics Inc Company Overview 32
• 5.12 Clemson University Company Overview 33
• 5.13 Cohera Medical Inc Company Overview 34
• 5.14 Covalent Medical, Inc. (Inactive) Company Overview 37
• 5.15 DSM Biomedical BV Company Overview 38
• 5.16 Elastagen Pty Ltd Company Overview 39
• 5.17 Ethicon Endo-Surgery Inc Company Overview 40
• 5.18 Gamma Therapeutics Inc Company Overview 41
• 5.19 GATT Technologies BV Company Overview 42
• 5.20 Grifols SA Company Overview 44
• 5.21 Grifols USA LLC Company Overview 45
• 5.22 Hemostasis LLC Company Overview 46
• 5.23 HyperBranch Medical Technology Inc Company Overview 50
• 5.24 Institute of Molecular Biology of Parana Company Overview 52
• 5.25 InVivo Therapeutics Corp Company Overview 53
• 5.26 Johns Hopkins University Company Overview 54
• 5.27 Kollodis BioSciences Inc Company Overview 55
• 5.28 Kuros Biosciences AG Company Overview 56
• 5.29 Laser Tissue Welding, Inc. Company Overview 58
• 5.30 LifeBond Ltd Company Overview 61
• 5.31 Medisse BV (Inactive) Company Overview 65
• 5.32 Pharming Group NV Company Overview 66
• 5.33 Polyganics BV Company Overview 67
• 5.34 Protein Polymer Technologies Inc (Inactive) Company Overview 73
• 5.35 Purdue University Company Overview 74
• 5.36 Samyang Biopharmaceuticals Corp Company Overview 75
• 5.37 Sealantis Ltd. Company Overview 76
• 5.38 Shanghai Haohai Biological Technology Co Ltd Company Overview 80
• 5.39 Surgical Sealants, Inc. Company Overview 82
• 5.40 Teijin Pharma Ltd Company Overview 83
• 5.41 Texas A&M University Company Overview 84
• 5.42 The Medicines Company Company Overview 86
• 5.43 Tissium SA Company Overview 87
• 5.44 University of Akron Company Overview 88

6 Tissue Sealants- Recent Developments 89

• 6.1 Nov 19, 2019: ThermoGenesis Holdings announces improved third quarter 2019 financial results and provides corporate update 89
• 6.2 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 91
• 6.3 Oct 31, 2019: Cesca Therapeutics to change name and ticker symbol to reflect new strategic focus 93
• 6.4 Oct 30, 2019: The Medicines Company reports third-quarter 2019 financial results and achievement of major milestones for inclisiran 94
• 6.5 Oct 30, 2019: CryoLife reports third quarter 2019 financial results 95
• 6.6 Oct 28, 2019: PolyNovo: Appointment non-executive director - Dr Robyn Elliott 96
• 6.7 Oct 24, 2019: Baxter reports preliminary third quarter 2019 operating results 96
• 6.8 Oct 21, 2019: Sean Salmon named executive vice president and group president of Medtronic Diabetes 98
• 6.9 Oct 15, 2019: Johnson & Johnson reports 2019 Third-Quarter Results 99
• 6.10 Oct 08, 2019: Samyang Biopharm USA expands and strengthens its US operations and makes additions to executive team in key business areas 100

7 Appendix 184

• 7.1 Methodology 184
• 7.2 About GlobalData 187
• 7.3 Contact Us 187